Advertisement

Picture Berlin Partner Hotspot for Startups 650x80px
Document › Details

CureVac AG. (11/21/18). "Press Release: CureVac to Present at the 19th Annual Piper Jaffray Healthcare Conference". Tübingen & Boston, MA.

Region Region New York, NY
  Country United States (USA)
Organisations Organisation CureVac AG
  Group CureVac (Group)
  Organisation 2 Piper Jaffray & Co. (NYSE: PJC)
  Today Piper Sandler Companies (NYSE: PIPR)
  Group Piper Sandler (Group)
Products Product Piper Jaffray Annual Healthcare Conference 2018 New York
  Product 2 mRNA technology
Index term Index term CureVac–Piper Jaffray: investor conference, 201811 supply service CureVac presents at Piper Jaffray Healthcare Conference 2018
Persons Person Menichella, Daniel L. (Dan) (Kaleido Biosciences 202010– CEO before CureVac + Bamboo Therapeutics + AGTC + Zyngenia)
  Person 2 Beck, Matthew L. S. (Matt) (CureVac 201806– VP Investor Relations before Solebury Trout)
     


CureVac AG, a fully integrated biopharmaceutical company pioneering the field of mRNA-based drugs, today announced that Dan Menichella, Chief Executive Officer, will present a corporate overview at the 19th Annual Piper Jaffray Healthcare Conference in New York on Tuesday, November 27, 2018 at 10:50 a.m. ET.

A live audio broadcast of the presentation will be available at www.curevac.com/en/newsroom/curevacevents. An archived replay of the presentation will be available on the company’s website for 3 months following the presentation.


About CureVac AG

CureVac is a leading company in the field of messenger RNA (mRNA) technology with more than 18 years’ expertise in handling and optimizing this versatile molecule for medical purposes. The principle of CureVac's proprietary technology is the use of mRNA as a data carrier to instruct the human body to produce its own proteins capable of fighting a wide range of diseases. The company applies its technologies for the development of cancer therapies, prophylactic vaccines and molecular therapies.

To date, CureVac has received approximately $420 million (€400 million) in equity investments including significant investments from SAP founder Dietmar Hopp’s dievini and an investment of $52 million from the Bill & Melinda Gates Foundation. CureVac has also entered into collaborations with multinational corporations and organizations, including Boehringer Ingelheim, Eli Lilly & Co, CRISPR Therapeutics, Arcturus Therapeutics, Acuitas, and the Bill & Melinda Gates Foundation.

For more information, please visit www.curevac.com or follow us on Twitter at @CureVacAG.


***

Investor Contact

Matthew Beck, Vice President Investor Relations
CureVac AG, Boston, MA, United States
T: +1 917-415-1750
matthew.beck@curevac.com

   
Record changed: 2019-03-02

Advertisement

Picture EBD Group Connector Personal Networking in Life Sciences 650x80

More documents for CureVac (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

Picture [iito] Back into Ad 650x80px




» top